InMed Pharmaceuticals Inc.
INMNasdaq
$1.52
↓ -4.4%Jul 17 close · end-of-day
Price
1Y↓ -42.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.2M
Enterprise Value
$952,720.68
P/E
—
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$8.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-123.5%
ROIC
—
Debt / Equity
—
Net Cash
$5.2M
Return 1Y
-42.3%
Company profile
InMed Pharmaceuticals Inc. researches and develops cannabinoid-based therapies. Lead product INM-755, a cannabinoidol topical cream, is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing InM-088, which is in preclinical studies for the. treatment of glaucoma and pain.
- CEO
- Eric A. Adams
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- British Columbia
- Website
- inmedpharma.com
Earnings
INM Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.73↓ -62.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.9M | $1.1M | $4.1M | $4.6M | $4.9M |
| Gross profit | — | $543,546.00 | $1.4M | $1.1M | $1.7M |
| Operating income | -$10.2M | -$18.6M | -$7.9M | — | — |
| Net income | -$10.2M | -$18.6M | -$7.9M | -$7.7M | -$8.2M |
| Diluted EPS | -$37.96 | -$33.17 | -$3.25 | -$20.14 | -$8.36 |
| Operating cash flow | -$9.8M | -$15.6M | -$7.3M | -$7.0M | -$7.8M |
| Free cash flow | -$9.8M | -$15.6M | -$7.4M | -$7.0M | -$7.8M |
| Gross margin | — | 49.9% | 33.9% | 23.9% | 34.5% |
| Operating margin | -535.9% | -1707.3% | -192.2% | — | — |
| Net margin | -535.9% | -1707.3% | -192.2% | -166.9% | -165.1% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.3M | $1.1M | $1.3M | $1.3M | $1.1M | $820,188.00 | — |
| Gross profit | $466,071.00 | $493,413.00 | $460,894.00 | $175,625.00 | $576,654.00 | $403,159.00 | $184,194.00 | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$1.9M | -$1.7M | -$2.6M | -$2.1M | -$1.8M | -$1.7M | -$2.0M | -$3.0M |
| Diluted EPS | $2.39 | -$2.71 | -$3.64 | -$1.94 | -$0.07 | -$0.44 | -$0.51 | -$0.73 |
| Operating cash flow | -$1.0M | -$1.8M | -$2.5M | -$1.7M | -$1.8M | -$1.6M | -$2.4M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 36.3% | 39.0% | 41.5% | 13.9% | 44.2% | 36.0% | 22.5% | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | -151.0% | -132.7% | -231.6% | -168.1% | -137.1% | -154.2% | -247.3% | — |
Company news
May 20, 2026
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Vivo Opportunity, LLC | Buy | 19 | $1.55 | $29.45 | filing |
| 2026-07-16 | Vivo Opportunity, LLC | Buy | 2 | $1.55 | $3.10 | filing |
| 2026-07-15 | Vivo Opportunity, LLC | Buy | 13,761 | $1.55 | $21,329.55 | filing |
| 2026-07-15 | Vivo Opportunity, LLC | Buy | 1,389 | $1.55 | $2,152.95 | filing |
| 2026-07-15 | ADAR1 Capital Management, LLC | Buy | 1,000 | $1.56 | $1,555.00 | filing |
| 2026-07-14 | Vivo Opportunity, LLC | Buy | 4,882 | $1.55 | $7,567.10 | filing |
| 2026-07-14 | Vivo Opportunity, LLC | Buy | 493 | $1.55 | $764.15 | filing |
| 2026-07-02 | Vivo Opportunity, LLC | Buy | 1,460 | $1.55 | $2,263.00 | filing |
| 2026-07-02 | Vivo Opportunity, LLC | Buy | 147 | $1.55 | $227.85 | filing |
| 2026-07-01 | Vivo Opportunity, LLC | Buy | 3,946 | $1.55 | $6,116.30 | filing |
| 2026-07-01 | Vivo Opportunity, LLC | Buy | 398 | $1.55 | $616.90 | filing |
| 2026-06-30 | Vivo Opportunity, LLC | Buy | 545 | $1.54 | $839.30 | filing |
| 2026-06-30 | Vivo Opportunity, LLC | Buy | 55 | $1.54 | $84.70 | filing |
| 2026-06-08 | Vivo Opportunity, LLC | Buy | 29,518 | $1.52 | $44,867.36 | filing |
| 2026-06-08 | Vivo Opportunity, LLC | Buy | 2,982 | $1.52 | $4,532.64 | filing |
| 2026-06-05 | Vivo Opportunity, LLC | Buy | 49,966 | $1.57 | $78,446.62 | filing |
| 2026-06-05 | Vivo Opportunity, LLC | Buy | 5,045 | $1.57 | $7,920.65 | filing |
| 2026-06-04 | Vivo Opportunity, LLC | Buy | 6,125 | $1.57 | $9,616.25 | filing |
| 2026-06-04 | Vivo Opportunity, LLC | Buy | 618 | $1.57 | $970.26 | filing |
| 2026-06-03 | Vivo Opportunity, LLC | Buy | 7,069 | $1.55 | $10,956.95 | filing |
| 2026-06-03 | Vivo Opportunity, LLC | Buy | 714 | $1.55 | $1,106.70 | filing |
| 2026-06-02 | Vivo Opportunity, LLC | Buy | 20,753 | $1.52 | $31,544.56 | filing |
| 2026-06-02 | Vivo Opportunity, LLC | Buy | 2,095 | $1.52 | $3,184.40 | filing |
| 2026-06-01 | Vivo Opportunity, LLC | Buy | 14,838 | $1.55 | $22,998.90 | filing |
| 2026-06-01 | Vivo Opportunity, LLC | Buy | 1,498 | $1.55 | $2,321.90 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.